Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: A potential role of sigma-1 receptors

Annals of General Psychiatry

Volumn 9, Issue , 2010, Pages

  Furuse, Tsutomu ^a   Hashimoto, Kenji ^b  

^a ASAHIKAWA RED CROSS HOSPITAL   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; FLUVOXAMINE; OPIATE AGONIST; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SIGMA 1 OPIATE RECEPTOR;

ADULT; AKATHISIA; ARTICLE; CASE REPORT; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MENTAL PATIENT; MONOTHERAPY; RESTLESS LEGS SYNDROME; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; WEIGHT GAIN;

EID: 77951189971     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-9-11     Document Type: Article

References (15)

1. Iqbal N, Lambert T, Masand P. Akathisia: problem of history or concern of today. CNS Spectr 2007, 12(Suppl 14):1-13.
2. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A, Assunção-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 2009, 70:627-643. 10.4088/JCP.08r04210, 19389331.
3. Kane JH. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001, 11(Suppl 4):S397-S403. 10.1016/S0924-977X(01)00109-2, 11587887.
4. Kane JM, Barnes TR, Correll CU, Sachs G, Buckley P, Eudicone J, McQuade R, Van Tran Q, Pikalov A, Assunção-Talbott S. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol 2010,
5. Hayashi T, Su TP. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 2004, 18:269-284. 10.2165/00023210-200418050-00001, 15089113.
6. Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 2006, 12:3857-3876. 10.2174/138161206778559614, 17073684.
7. Maurice T, Su TP. The pharmacology of sigma-1 receptors. Pharmacol Ther 2009, 124:195-206. 10.1016/j.pharmthera.2009.07.001, 19619582.
8. Ishikawa M, Hashimoto K. The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases. J Receptor Ligand Channel Res 2010, 3:25-36.
9. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell 2007, 131:596-610. 10.1016/j.cell.2007.08.036, 17981125.
10. Hayashi T, Stahl SM. The sigma-1 receptor and its role in the treatment of mood disorders. Drugs Future 2009, 34:137-146.
11. Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996, 307:117-119. 10.1016/0014-2999(96)00254-3, 8831113.
12. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem. 2009, 9(3):197-204.
13. Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, Oda K, Miyatake R, Fujisaki M, Shimizu E, Shirayama Y, Iyo M, Hashimoto K. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol Psychiatry 2007, 62:878-883. 10.1016/j.biopsych.2007.04.001, 17662961.
14. Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L'Italien G, McQuade RD, Beuzen JN. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients. Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry 2007, 22:433-443. 10.1016/j.eurpsy.2007.03.002, 17555947.
15. Barnes TR. A rating scale for drug-induced akathisia. Bri J Psychiatry 1989, 154:672-676.